Fewer Blacks Than Whites Receive Surgery for Early Stage Lung Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

NEW YORK-Fewer blacks than whites receive potentially curative surgery for early stage lung cancer, and this disparity is substantially responsible for lower survival rates for black patients, according to researchers at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute.

NEW YORK—Fewer blacks than whites receive potentially curative surgery for early stage lung cancer, and this disparity is substantially responsible for lower survival rates for black patients, according to researchers at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute.

“In our study, black men and women were 13% less likely to have surgery for early stage lung cancer, and this translated into lower overall survival. It is a phenomenon that appeared independent of socioeconomic status,” said Peter B. Bach, MD, first author of the study and an epidemiologist at Memorial Sloan-Kettering. “We believe that fewer blacks will die of this disease if more receive the best available treatment.”

The researchers analyzed data from nearly 11,000 patients age 65 and older who were diagnosed with early stage non-small-cell lung cancer (NSCLC).

Treatment of early stage NSCLC was chosen for analysis because surgery offers the possibility of cure. “The optimal strategy is unambiguous,” Dr. Bach said. An average of 40% of patients undergoing surgery are alive after 5 years vs only 5% of patients who do not have surgery.

Dr. Bach and his colleagues looked at the experience of 10,984 Medicare patients diagnosed with stage I or II non-small-cell lung cancer between 1985 and 1993; 860 (8%) were black, and 10,124 (92%) were non-Hispanic white. The patients all lived within one of 10 regions included in the NCI’s Surveillance, Epidemiology and End Results (SEER) database. All were covered by Medicare, either through an HMO or a traditional indemnity plan.

By linking Medicare and SEER data, the researchers were able to obtain comprehensive information about each patient, including diagnosis, coexisting conditions, treatment, availability of health care, and patient demographics.

The researchers found that 64% of the black patients in the study underwent surgery, compared with 76.7% of the white patients (P < .001).

This disparity translated into higher overall mortality for blacks. At 5 years, 26% of the black patients were still alive, compared with 34% of the white patients (N Engl J Med 341:1198-1205, 1999). If whites and blacks were to receive surgical treatment equally, the authors estimate that the survival of black patients would rise to 31%.

Five-year survival rates were comparable for blacks and whites who received surgery (39.1% and 42.9%, respectively, P = .10), and for blacks and white who did not undergo surgery (4% and 5%, respectively, P = .25).

Because the study did not examine the reasons why black patients undergo surgery less frequently, “it is difficult to know why this disparity exists,” Dr. Bach said. “One explanation could be that blacks are not offered the surgery as frequently; another is that they are choosing not to have surgery.”

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content